{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T05:33:04Z","timestamp":1788845584980,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:00:00Z","timestamp":1679875200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteogenesis imperfecta (OI) is a rare bone disease that is associated with fractures and low bone mass. Sclerostin inhibition is being evaluated as a potential approach to increase bone mass in OI. We had previously found that in <jats:italic>Col1a1<\/jats:italic><jats:sup>Jrt\/+<\/jats:sup> mice, a model of severe OI, treatment with an anti-sclerostin antibody had a minor effect on the skeletal phenotype. In the present study, we assessed the effect of genetic sclerostin inactivation in the <jats:italic>Col1a1<\/jats:italic><jats:sup>Jrt\/+<\/jats:sup> mouse. We crossed <jats:italic>Col1a1<\/jats:italic><jats:sup>Jrt\/+<\/jats:sup> mice with <jats:italic>Sost<\/jats:italic> knockout mice to generate <jats:italic>Sost<\/jats:italic>-deficient <jats:italic>Col1a1<\/jats:italic><jats:sup>Jrt\/+<\/jats:sup> mice and assessed differences between <jats:italic>Col1a1<\/jats:italic><jats:sup>Jrt\/+<\/jats:sup> mice with homozygous <jats:italic>Sost<\/jats:italic> deficiency and <jats:italic>Col1a1<\/jats:italic><jats:sup>Jrt\/+<\/jats:sup> mice with heterozygous <jats:italic>Sost<\/jats:italic> deficiency. We found that <jats:italic>Col1a1<\/jats:italic><jats:sup>Jrt\/+<\/jats:sup> mice with homozygous <jats:italic>Sost<\/jats:italic> deficiency had higher body mass, femur length, trabecular bone volume, cortical thickness and periosteal diameter as well as increased biomechanical parameters of bone strength. Differences between genotypes were larger at the age of 14\u00a0weeks than at 8\u00a0weeks of age. Transcriptome analysis of RNA extracted from the tibial diaphysis revealed only 5 differentially regulated genes. Thus, genetic inactivation of <jats:italic>Sost<\/jats:italic> increased bone mass and strength in the <jats:italic>Col1a1<\/jats:italic><jats:sup>Jrt\/+<\/jats:sup> mouse. It appears from these observations that the degree of <jats:italic>Sost<\/jats:italic> suppression that is required for eliciting a beneficial response can vary with the genetic cause of OI.<\/jats:p>","DOI":"10.1038\/s41598-023-32221-3","type":"journal-article","created":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T17:03:23Z","timestamp":1679936603000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Effect of sclerostin inactivation in a mouse model of severe dominant osteogenesis imperfecta"],"prefix":"10.1038","volume":"13","author":[{"given":"Juliana","family":"Marulanda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine T.","family":"Tauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iris","family":"Boraschi-Diaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghalib","family":"Bardai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,27]]},"reference":[{"key":"32221_CR1","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1016\/S0140-6736(15)00728-X","volume":"387","author":"A Forlino","year":"2016","unstructured":"Forlino, A. & Marini, J. C. Osteogenesis imperfecta. Lancet 387, 1657\u20131671. https:\/\/doi.org\/10.1016\/S0140-6736(15)00728-X (2016).","journal-title":"Lancet"},{"key":"32221_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.bone.2019.04.021","volume":"126","author":"ME Robinson","year":"2019","unstructured":"Robinson, M. E. & Rauch, F. Mendelian bone fragility disorders. Bone 126, 11\u201317. https:\/\/doi.org\/10.1016\/j.bone.2019.04.021 (2019).","journal-title":"Bone"},{"key":"32221_CR3","doi-asserted-by":"publisher","first-page":"e10174","DOI":"10.1002\/jbm4.10174","volume":"3","author":"JT Tauer","year":"2019","unstructured":"Tauer, J. T., Robinson, M. E. & Rauch, F. Osteogenesis imperfecta: New perspectives from clinical and translational research. JBMR Plus 3, e10174. https:\/\/doi.org\/10.1002\/jbm4.10174 (2019).","journal-title":"JBMR Plus"},{"key":"32221_CR4","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1146\/annurev-physiol-021119-034332","volume":"82","author":"AG Robling","year":"2020","unstructured":"Robling, A. G. & Bonewald, L. F. The osteocyte: New insights. Annu. Rev. Physiol. 82, 485\u2013506. https:\/\/doi.org\/10.1146\/annurev-physiol-021119-034332 (2020).","journal-title":"Annu. Rev. Physiol."},{"key":"32221_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.bone.2016.10.010","volume":"96","author":"AH van Lierop","year":"2017","unstructured":"van Lierop, A. H., Appelman-Dijkstra, N. M. & Papapoulos, S. E. Sclerostin deficiency in humans. Bone 96, 51\u201362. https:\/\/doi.org\/10.1016\/j.bone.2016.10.010 (2017).","journal-title":"Bone"},{"key":"32221_CR6","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman, F. et al. Romosozumab treatment in postmenopausal women with osteoporosis. N. Engl. J. Med. 375, 1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMoa1607948 (2016).","journal-title":"N. Engl. J. Med."},{"key":"32221_CR7","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1002\/jbmr.3143","volume":"32","author":"FH Glorieux","year":"2017","unstructured":"Glorieux, F. H. et al. BPS804 anti-sclerostin antibody in adults with moderate osteogenesis imperfecta: Results of a randomized phase 2a trial. J. Bone Miner. Res. 32, 1496\u20131504. https:\/\/doi.org\/10.1002\/jbmr.3143 (2017).","journal-title":"J. Bone Miner. Res."},{"key":"32221_CR8","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bone.2014.10.012","volume":"71","author":"BP Sinder","year":"2015","unstructured":"Sinder, B. P. et al. Rapidly growing Brtl\/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment. Bone 71, 115\u2013123. https:\/\/doi.org\/10.1016\/j.bone.2014.10.012 (2015).","journal-title":"Bone"},{"key":"32221_CR9","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1007\/s00198-014-2737-y","volume":"25","author":"BP Sinder","year":"2014","unstructured":"Sinder, B. P. et al. Adult Brtl\/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength. Osteoporos. Int. 25, 2097\u20132107. https:\/\/doi.org\/10.1007\/s00198-014-2737-y (2014).","journal-title":"Osteoporos. Int."},{"key":"32221_CR10","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bone.2019.04.011","volume":"124","author":"M Cardinal","year":"2019","unstructured":"Cardinal, M. et al. Sclerostin antibody reduces long bone fractures in the oim\/oim model of osteogenesis imperfecta. Bone 124, 137\u2013147. https:\/\/doi.org\/10.1016\/j.bone.2019.04.011 (2019).","journal-title":"Bone"},{"key":"32221_CR11","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/jbmr.2776","volume":"31","author":"I Grafe","year":"2016","unstructured":"Grafe, I. et al. Sclerostin antibody treatment improves the bone phenotype of Crtap(\u2212\/\u2212) mice, a model of recessive osteogenesis imperfecta. J. Bone Miner. Res. 31, 1030\u20131040. https:\/\/doi.org\/10.1002\/jbmr.2776 (2016).","journal-title":"J. Bone Miner. Res."},{"key":"32221_CR12","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.bone.2014.06.015","volume":"66","author":"A Roschger","year":"2014","unstructured":"Roschger, A. et al. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone 66, 182\u2013188. https:\/\/doi.org\/10.1016\/j.bone.2014.06.015 (2014).","journal-title":"Bone"},{"key":"32221_CR13","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1359\/jbmr.090730","volume":"25","author":"I Kramer","year":"2010","unstructured":"Kramer, I., Loots, G. G., Studer, A., Keller, H. & Kneissel, M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J. Bone Miner. Res. 25, 178\u2013189. https:\/\/doi.org\/10.1359\/jbmr.090730 (2010).","journal-title":"J. Bone Miner. Res."},{"key":"32221_CR14","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1002\/jbmr.2177","volume":"29","author":"F Chen","year":"2014","unstructured":"Chen, F. et al. First mouse model for combined osteogenesis imperfecta and Ehlers-Danlos syndrome. J. Bone Miner. Res. 29, 1412\u20131423. https:\/\/doi.org\/10.1002\/jbmr.2177 (2014).","journal-title":"J. Bone Miner. Res."},{"key":"32221_CR15","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1359\/jbmr.080216","volume":"23","author":"X Li","year":"2008","unstructured":"Li, X. et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23, 860\u2013869. https:\/\/doi.org\/10.1359\/jbmr.080216 (2008).","journal-title":"J. Bone Miner. Res."},{"key":"32221_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1002\/jbmr.1805","volume":"28","author":"DW Dempster","year":"2013","unstructured":"Dempster, D. W. et al. Standardized nomenclature, symbols, and units for bone histomorphometry: A 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 28, 2\u201317. https:\/\/doi.org\/10.1002\/jbmr.1805 (2013).","journal-title":"J. Bone Miner. Res."},{"key":"32221_CR17","doi-asserted-by":"publisher","first-page":"5290","DOI":"10.3390\/ijms22105290","volume":"22","author":"P Moffatt","year":"2021","unstructured":"Moffatt, P., Boraschi-Diaz, I., Marulanda, J., Bardai, G. & Rauch, F. Calvaria bone transcriptome in mouse models of osteogenesis imperfecta. Int. J. Mol. Sci. 22, 5290. https:\/\/doi.org\/10.3390\/ijms22105290 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"32221_CR18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nbt.2450","volume":"31","author":"C Trapnell","year":"2013","unstructured":"Trapnell, C. et al. Differential analysis of gene regulation at transcript resolution with RNA-seq. Nat. Biotechnol. 31, 46\u201353. https:\/\/doi.org\/10.1038\/nbt.2450 (2013).","journal-title":"Nat. Biotechnol."},{"key":"32221_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders, S., Pyl, P. T. & Huber, W. HTSeq\u2014A Python framework to work with high-throughput sequencing data. Bioinformatics 31, 166\u2013169. https:\/\/doi.org\/10.1093\/bioinformatics\/btu638 (2015).","journal-title":"Bioinformatics"},{"key":"32221_CR20","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/gb-2010-11-10-r106","volume":"11","author":"S Anders","year":"2010","unstructured":"Anders, S. & Huber, W. Differential expression analysis for sequence count data. Genome Biol. 11, R106. https:\/\/doi.org\/10.1186\/gb-2010-11-10-r106 (2010).","journal-title":"Genome Biol."},{"key":"32221_CR21","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1093\/bioinformatics\/bts196","volume":"28","author":"DS DeLuca","year":"2012","unstructured":"DeLuca, D. S. et al. RNA-SeQC: RNA-seq metrics for quality control and process optimization. Bioinformatics 28, 1530\u20131532. https:\/\/doi.org\/10.1093\/bioinformatics\/bts196 (2012).","journal-title":"Bioinformatics"},{"key":"32221_CR22","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00223-019-00648-4","volume":"106","author":"L Albiol","year":"2020","unstructured":"Albiol, L. et al. Effects of long-term sclerostin deficiency on trabecular bone mass and adaption to limb loading differ in male and female mice. Calcif. Tissue Int. 106, 415\u2013430. https:\/\/doi.org\/10.1007\/s00223-019-00648-4 (2020).","journal-title":"Calcif. Tissue Int."},{"key":"32221_CR23","doi-asserted-by":"publisher","first-page":"9435","DOI":"10.1038\/s41598-017-09653-9","volume":"7","author":"D Pflanz","year":"2017","unstructured":"Pflanz, D. et al. Sost deficiency led to a greater cortical bone formation response to mechanical loading and altered gene expression. Sci. Rep. 7, 9435. https:\/\/doi.org\/10.1038\/s41598-017-09653-9 (2017).","journal-title":"Sci. Rep."},{"key":"32221_CR24","doi-asserted-by":"publisher","first-page":"116401","DOI":"10.1016\/j.bone.2022.116401","volume":"160","author":"M Koide","year":"2022","unstructured":"Koide, M. et al. Evidence for the major contribution of remodeling-based bone formation in sclerostin-deficient mice. Bone 160, 116401. https:\/\/doi.org\/10.1016\/j.bone.2022.116401 (2022).","journal-title":"Bone"},{"key":"32221_CR25","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ar.1092260402","volume":"226","author":"HM Frost","year":"1990","unstructured":"Frost, H. M. Skeletal structural adaptations to mechanical usage (SATMU): 1. Redefining Wolff\u2019s law: The bone modeling problem. Anat. Rec. 226, 403\u2013413 (1990).","journal-title":"Anat. Rec."},{"key":"32221_CR26","doi-asserted-by":"publisher","first-page":"18514","DOI":"10.1074\/jbc.M116.723379","volume":"291","author":"S Baumann","year":"2016","unstructured":"Baumann, S. & Hennet, T. Collagen accumulation in osteosarcoma cells lacking GLT25D1 collagen galactosyltransferase. J. Biol. Chem. 291, 18514\u201318524. https:\/\/doi.org\/10.1074\/jbc.M116.723379 (2016).","journal-title":"J. Biol. Chem."},{"key":"32221_CR27","doi-asserted-by":"publisher","first-page":"6392","DOI":"10.1210\/jc.2005-1235","volume":"90","author":"JC Gardner","year":"2005","unstructured":"Gardner, J. C. et al. Bone mineral density in sclerosteosis; affected individuals and gene carriers. J. Clin. Endocrinol. Metab. 90, 6392\u20136395. https:\/\/doi.org\/10.1210\/jc.2005-1235 (2005).","journal-title":"J. Clin. Endocrinol. Metab."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32221-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32221-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32221-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T05:06:07Z","timestamp":1679979967000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-32221-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,27]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["32221"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-32221-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,27]]},"assertion":[{"value":"18 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Frank Rauch: Ultragenyx Inc: Study grant to institution. Catabasis: Study grant to institution. Ibsen: Advisory Board. Sanofi: Advisory Board.\u00a0The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5010"}}